Efficacy and safety of camrelizumab in metastatic lung cancer: a single-center, prospective cohort study

Abstract

Objective: To explore the efficacy and safety of camrelizumab in the treatment of patients with metastatic lung cancer in the real world. Methods: A prospective cohort study was designed to include a total of 44 patients with metastatic lung cancer who received camrelizumab treatment in xx Hospital between July 2019 and May 2020, with a follow-up endpoint set on August 1, 2020. The primary endpoints were objective response rate (ORR) and safety. Secondary endpoint measures included progression-free survival (PFS), and overall survival (OS). Cox regression was used for the analysis of factors associated with PFS. Results: The ORR of 44 patients was 27.3% (including 1 complete response and 10 partial responses), and 7 patients had disease progression. The PFS was 8 months (2-11 months), and the OS had not been reached. Multivariate Cox regression analysis showed that the number of metastatic sites ≤ 1 (HR = 0.202, 95% CI: 0.065-0.637, P < 0.01) was associated with PFS. The most common adverse event was anemia (47.7%, 21/44), all grade 1 to 2. Five patients (9.1%) had grade 3 adverse events, including 2 cases of neutropenia, 1 case of leukopenia, and 2 cases of immune pneumonitis. Other common adverse events included thrombocytopenia (18.2%), hemangioma (15.9%), and hypothyroidism (11.4%), all of which were grade 1-2. There were no deaths due to adverse events. Conclusion: In the real world, camrelizumab has definite efficacy and controllable toxicity in patients with metastatic lung cancer, with high safety